BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6.5%

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shot up 6.5% on Monday . The company traded as high as $6.61 and last traded at $6.58. 922,568 shares were traded during trading, a decline of 74% from the average session volume of 3,510,592 shares. The stock had previously closed at $6.18.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BCRX. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. JMP Securities raised their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Trading Up 4.7 %

The company has a 50 day moving average price of $5.78 and a 200 day moving average price of $5.62. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.00 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. During the same period last year, the firm earned ($0.28) earnings per share. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Machelle Sanders sold 4,689 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the sale, the director now directly owns 27,742 shares of the company’s stock, valued at $166,452. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other BioCryst Pharmaceuticals news, Director Machelle Sanders sold 4,689 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the transaction, the director now directly owns 27,742 shares in the company, valued at $166,452. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Amy E. Mckee sold 8,600 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now owns 27,831 shares in the company, valued at $175,891.92. The disclosure for this sale can be found here. Insiders purchased a total of 103,601 shares of company stock valued at $596,338 over the last three months. Company insiders own 4.80% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock valued at $108,978,000 after acquiring an additional 302,270 shares during the last quarter. Norges Bank acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $13,278,000. Rafferty Asset Management LLC increased its position in BioCryst Pharmaceuticals by 18.3% during the fourth quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock worth $5,724,000 after buying an additional 147,699 shares during the last quarter. Braidwell LP increased its position in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock worth $34,254,000 after buying an additional 355,497 shares during the last quarter. Finally, Los Angeles Capital Management LLC increased its position in BioCryst Pharmaceuticals by 68.0% during the first quarter. Los Angeles Capital Management LLC now owns 89,614 shares of the biotechnology company’s stock worth $455,000 after buying an additional 36,284 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.